Soligenix Reports Extension Of Hypericin Orphan Designation Beyond Cutaneous T-cell Lymphoma

(RTTNews) - Soligenix, Inc. (SNGX) said the Office of Orphan Products Development of FDA has granted orphan drug designation to the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma.

"The FDA's decision to grant and expand our hypericin orphan drug designation beyond cutaneous T-cell lymphoma signifies an important step for Soligenix as we continue to advance the program toward NDA filing in the first half of 2022," said Christopher Schaber, President & Chief Executive Officer of Soligenix.

Shares of Soligenix were up 17% in pre-market trade on Thursday.